43.2 percent missed opportunity rate reported for germline genetic testing, risk-reducing surgery in those with affected first-degree relative. HealthDay News — A considerable proportion of patients ...
Opportunistic salpingectomy (OS) is feasible but not performed in almost a quarter of patients later diagnosed with high-grade serous carcinoma (HGSC), and about 40% of patients with a first-degree ...
Department of Oral Implantology, The Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China State Key Laboratory Cultivation Base of Research, Prevention and ...
Researchers at Queen’s University of Belfast and collaborators have developed a DNA vaccine against high-grade serous ovarian cancer. The vaccine encodes PRAME, which the researchers found to be ...
The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the treatment of adults with KRAS-mutated, recurrent low-grade serous ovarian ...
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...
High-grade serous ovarian cancer (HGSOC) is a highly aggressive and deadly gynecological cancer, with metastasis being a key factor in its poor prognosis. Historically, HGSOC was thought to spread ...
An epiretinal membrane (ERM) is an eye condition where a layer of cells forms on the inside of your retina. This layer of cells is called a membrane. Many people with this condition don’t know that ...
Allan Albig receives funding from the National Institute of Health. Think back to that basic biology class you took in high school. You probably learned about organelles, those little “organs” inside ...
Epiretinal membrane (ERM) is a semi-clear membrane that can form over your retina’s inner surface. It often causes minimal symptoms, but some people have vision loss or distorted vision. Your retina ...
Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...